Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
DBV Technologies, a global clinical stage biopharmaceutical company, seeks an operational leader to guard and optimize 3PL-driven product distribution from warehouse to patient. You will drive forecast accuracy, coordinate between commercial sales and supply chain execution, and protect product availability while minimizing excess inventory.
You will oversee GDP-compliant distribution and serialization, ensuring audit readiness and continuous process improvement.
To serve as operational guardian of the physical product, overseeing 3PL operations and product integrity from warehouse to patient. To drive accountability of Forecast Accuracy, serve as a sync between commercial sales forecast and supply chain execution, ensuring 100% product availability with minimal inventory waste. Protects the company from stocking out (lost revenue) or overstocking (wasted opportunity cost of capital). Ensuring operational continuity of distribution operations with compliance. Oversee Commercial as well as Samples & Demo product distribution operations.
To serve as operational guardian of the physical product, overseeing 3PL operations and product integrity from warehouse to patient. To drive accountability of Forecast Accuracy, serve as a sync between commercial sales forecast and supply chain execution, ensuring 100% product availability with minimal inventory waste. Protects the company from stocking out (lost revenue) or overstocking (wasted opportunity cost of capital). Ensuring operational continuity of distribution operations with compliance. Oversee Commercial as well as Samples & Demo product distribution operations.
Warren, New Jersey - 3 days on site minimum
120-135K
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.